The combined application of the STAT3 signaling pathway small-molecule inhibitor YHO-1701 and PD-1/PD-L1 blockade significantly inhibits tumor growth in immunotherapy-resistant CMS5a fibrosarcoma mouse models, thus providing crucial experimental evidence for developing novel cancer immunotherapy combination strategies [70]. This evidence concerns the gene CD274 and neoplasm.